We are live on ! Find out more
PM

Prosight Management Portfolio holdings

AUM $580M
1-Year Est. Return 29.81%
This Fund
S&P 500
This Quarter Est. Return
+1.17%
1 Year Est. Return
+29.81%
3 Year Est. Return
+39.55%
5 Year Est. Return
-6.93%
10 Year Est. Return
–
AUM
$406M
AUM Growth
+$71.8M
Cap. Flow
+$62M
Cap. Flow %
15.25%
Top 10 Hldgs %
55.4%
Holding
62
New
16
Increased
17
Reduced
12
Closed
17

Top Buys

Rank Stock Value
1
MCK icon
McKesson
MCK
+$19.9M
2
ABCL icon
AbCellera Biologics
ABCL
+$18.6M
3
DXCM icon
DexCom
DXCM
+$9.09M
4
JANX icon
Janux Therapeutics
JANX
+$8.92M
5
BBIO icon
BridgeBio Pharma
BBIO
+$7.53M

Top Sells

Rank Stock Value
1
KELYA icon
Kelly Services Class A
KELYA
+$10.5M
2
LKFT
Lakefront Biotherapeutics American Depositary Shares
LKFT
+$8.74M
3
ALKS icon
Alkermes
ALKS
+$6.63M
4
KIDS icon
OrthoPediatrics
KIDS
+$5.76M
5
OPCH icon
Option Care Health
OPCH
+$5.68M

Sector Composition

Rank Sector Weight
1 Healthcare 94.39%
2 Miscellaneous 2.95%
3 Industrials 2.65%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
COGT icon
26
Cogent Biosciences
COGT
$6.02B
$4.44M 1.09%
410,830
-89,170
-18% -$868K
FLNA
27
PUT
Filana Therapeutics
FLNA
$44.9M
$4.38M 1.08%
+148,900
New +$3.43M
BPMC
28
DELISTED
Blueprint Medicines
BPMC
$4.36M 1.07%
+47,100
New +$4.68M
TECX
29
Tectonic Therapeutic
TECX
$696M
$4.17M 1.03%
137,614
+70,153
+104% +$1.28M
CTMX icon
30
CytomX Therapeutics
CTMX
$699M
$3.57M 0.88%
+3,022,109
New +$3.84M
SGHT icon
31
Sight Sciences
SGHT
$471M
$3.35M 0.82%
+531,222
New +$3.57M
VKTX icon
32
Viking Therapeutics
VKTX
$3.75B
$3.04M 0.75%
48,000
-67,000
-58% -$3.93M
RCKT icon
33
Rocket Pharmaceuticals
RCKT
$424M
$2.94M 0.72%
+159,369
New +$3.26M
CRBP icon
34
Corbus Pharmaceuticals
CRBP
$211M
$2.68M 0.66%
+130,000
New +$6.65M
MURA
35
DELISTED
Mural Oncology
MURA
$1.79M 0.44%
570,620
+95,162
+20% +$310K
MRVI icon
36
Maravai LifeSciences
MRVI
$1.14B
$1.73M 0.43%
+208,200
New +$1.8M
VINC
37
DELISTED
Vincerx Pharma, Inc. Common Stock
VINC
$1.58M 0.39%
110,325
-14,096
-11% -$193K
RNTX
38
Rein Therapeutics
RNTX
$65.7M
$1.32M 0.32%
372,157
+107,157
+40% +$286K
CRVL icon
39
PUT
CorVel
CRVL
$3.5B
$915K 0.23%
+8,400
New +$840K
SEM
40
DELISTED
Select Medical
SEM
$909K 0.22%
+48,377
New +$927K
OVID icon
41
Ovid Therapeutics
OVID
$547M
$860K 0.21%
729,208
-345,792
-32% -$361K
IMNM icon
42
Immunome
IMNM
$3.13B
$572K 0.14%
39,135
-25,865
-40% -$368K
IMRX icon
43
Immuneering
IMRX
$323M
$473K 0.12%
190,000
-360,000
-65% -$524K
ACHC icon
44
Acadia Healthcare
ACHC
$2.66B
$359K 0.09%
+5,666
New +$409K
STTK icon
45
CALL
Shattuck Labs
STTK
$707M
$303K 0.07%
+86,800
New +$324K
ADUS icon
46
Addus HomeCare
ADUS
$2.16B
– –
-12,500
Closed -$1.45M
ALKS icon
47
Alkermes
ALKS
$7.95B
– –
-275,000
Closed -$6.63M
BCRX icon
48
BioCryst Pharmaceuticals
BCRX
$2.51B
– –
-398,700
Closed -$2.46M
BMEA icon
49
Biomea Fusion
BMEA
$125M
– –
-124,377
Closed -$560K
CVS icon
50
CVS Health
CVS
$119B
– –
-40,000
Closed -$2.36M
1
2
3

Similar funds

SC
Stempoint Capital New York $581M AUM 373.68% 1-Year Est. Return
CCWM
Correct Capital Wealth Management Clayton, Missouri $580M AUM 16.45% 1-Year Est. Return
CMA
Cedar Mountain Advisors Lake Oswego, Oregon $581M AUM 18.16% 1-Year Est. Return
RIS
Retirement Income Solutions Ann Arbor, Michigan $581M AUM 19.42% 1-Year Est. Return
MFS
McNamara Financial Services Marshfield, Massachusetts $580M AUM 17.89% 1-Year Est. Return
GFI
Global Frontier Investments Charleston, South Carolina $581M AUM 8.55% 1-Year Est. Return
PWM
Praetorian Wealth Management Carmel, California $580M AUM 19.43% 1-Year Est. Return
CA
COFG Advisors Oak Brook, Illinois $579M AUM

Prosight Management's Q3 2024 Portfolio in Review

As of Q3 2024, Prosight Management held 62 positions worth $406M, up 21% from $335M the previous quarter. Its ten largest holdings account for 55% of the portfolio.

Prosight Management deployed $62M of net new capital in Q3 2024, opening 16 new positions and adding to 17 existing holdings. Its largest new stake was McKesson: 35,822 shares worth $17.7M.

By sector, the portfolio is most concentrated in Healthcare at 94% of assets, down from 95% a quarter earlier, followed by Miscellaneous and Industrials.

On the sell side, the largest reduction was Lakefront Biotherapeutics American Depositary Shares, an estimated $8.74M trimmed.

  • Prosight Management's largest Q3 2024 buy was McKesson: 35,822 shares worth $17.7M.
  • Prosight Management added most to AbCellera Biologics in Q3 2024, an estimated $18.6M increase.
  • Prosight Management's biggest Q3 2024 reduction was Lakefront Biotherapeutics American Depositary Shares, cutting an estimated $8.74M.
  • Prosight Management fully exited Kelly Services Class A in Q3 2024, selling an estimated $10.5M.
  • Prosight Management's ten largest holdings make up 55% of its $406M portfolio in Q3 2024.
  • Prosight Management opened 16 new positions and closed 17 in Q3 2024.
  • Prosight Management's portfolio value rose 21% quarter-over-quarter to $406M.

Based on Prosight Management's 13F filing for Q3 2024, filed 14 Nov 2024.